| abstract |
The use of modified human C3 convertase proteins in the manufacture of medicaments for reducing complement pathway products (inflammatory response products) particularly in circumstances where specific immune cell activation occurs but is unwanted. Conjugates comprising such proteins and a specific binding moiety, for example an antibody, are also provided, as is the use of such proteins and/or conjugates in therapy. DNA sequences encoding such proteins together with DNA constructs are also described. |